Global: EV/EBITDA health & pharmaceuticals 2022

Worldwide, the average value of enterprise value to earnings before interest, tax, depreciation and amortization (EV/EBITDA) in the health & pharmaceuticals sector as of 2022, was a multiple of approximately 17.4x. Healthcare information and technology companies saw the highest average valuation multiples as of January 2022 with 29.04x, a significant increase from a multiple of 19.9x in 2019.

Average EV/EBITDA multiples in the health & pharmaceuticals sector worldwide from 2019 to 2022, by industry

Characteristic	2019	2020	2021	2022
-	-	-	-	-
-	-	-	-	-
-	-	-	-	-
-	-	-	-	-
-	-	-	-	-
-	-	-	-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

January 2022

More information

Region

Worldwide

Survey time period

2019 to 2022

Supplementary notes

Values are as of January each year.
A total of 4,579 companies were included in the calculation for 2022, 4,326 for 2021, 4,023 for 2020 and 3,779 for 2019.

Enterprise value = Market value of equity + Market value of debt - Cash.
EBITDA = Estimated by adding depreciation and amortization back to operating income (EBIT).
Only positive EBITDA companies.

Figures for years 2019 to 2021 were previously published by the source.

Citation formats